Biosimilar ABP 798 Shows Similar Safety and Efficacy to Rituxan in Phase 3 Trial for Non-Hodgkin’s Lymphoma
News
ABP 798, a biosimilar to Rituxan (rituximab), is showing comparable efficacy results to its original product in a Phase 3 trial for non-Hodgkin’s lymphoma patients, the treatment’s co-developers, Amgen and Allergan, have ... Read more